Skip to main content

Table 2 Results of univariate analyses showing relationships between clinicopathological characteristics and lymph node metastases

From: Clinicopathological characteristics and treatment strategies in early gastric cancer: a retrospective cohort study

Variables

pT1a tumor

(n = 161)

pT1b1 tumor

(n = 43)

pT1b2 tumor

(n = 123)

 

pN(+)

p-value

pN(+)

p-value

pN(+)

p-value

Total

4/161 (2.5%)

 

4/43 (9.3%)

 

37/123 (30.1%)

 

   Sex

 

0.6269

 

0.2802

 

0.8309

   Male

3/88 (3.4%)

 

4/28 (14.3%)

 

26/88 (29.6%)

 

   Female

1/73 (1.4%)

 

0/15

 

11/35 (31.4%)

 

Age

 

0.6332

 

0.3449

 

0.8432

   < 65

3/91 (3.3%)

 

3/21 (14.3%)

 

16/51 (31.4%)

 

   65 ≤

1/70 (1.4%)

 

1/22 (4.6%)

 

21/72 (29.2%)

 

Main tumor site

 

0.1903

 

0.2707

 

0.1129

   Upper

0/19

 

0/3

 

3/21 (14.3%)

 

   Middle

4/89 (4.5%)

 

4/27 (14.8%)

 

17/59 (28.8%)

 

   Lower

0/53

 

0/13

 

17/43 (39.5%)

 

Clinical macro type

 

0.5655

 

0.5579

 

0.4764

   Depressed or excavated

3/131 (2.3%)

 

4/33 (12.1%)

 

27/96 (28.1%)

 

   Flat or elevated

1/30 (3.3%)

 

0/10

 

10/27 (37.0%)

 

Pathological macro type

 

1.0000

 

1.0000

 

0.4764

   Depressed

4/139 (2.9%)

 

4/37 (10.8%)

 

27/96 (28.1%)

 

   Flat or elevated

0/22

 

0/6

 

10/27 (37.0%)

 

Ulceration

 

0.1287

 

0.3235

 

0.4200

   No

0/72

 

1/23 (4.4%)

 

21/77 (27.3%)

 

   Yes

4/89 (4.5%)

 

3/20 (15.0%)

 

16/46 (34.8%)

 

Main histologic type

 

0.1252

 

0.4672

 

0.8441

   Differentiated

0/74

 

2/29 (6.9%)

 

19/66 (28.8%)

 

   Undifferentiated

4/87 (4.6%)

 

2/14 (14.3%)

 

18/57 (31.6%)

 

Pathological tumor size

 

1.0000

 

1.0000

 

0.0589

   ≤20 mm

1/60 (1.7%)

 

0/7

 

4/28 (14.3%)

 

   20 mm<

3/101 (2.5%)

 

4/36 (11.1%)

 

33/95 (34.7%)

 

Pathological tumor size

 

0.3083

 

1.0000

 

0.1730

   ≤30 mm

1/96 (1.0%)

 

2/21 (9.5%)

 

13/55 (23.6%)

 

   30 mm<

3/65 (4.6%)

 

2/22 (9.1%)

 

24/68 (35.3%)

 

Lymphatic invasion †

 

0.0731

 

0.5227

 

< 0.0001**

   L0

3/158 (1.9%)

 

3/36 (8.3%)

 

4/52 (7.7%)

 

   L1-2

1/3 (33.3%)

 

1/7 (14.3%)

 

33/71 (46.5%)

 

Venous invasion †

 

1.0000

 

1.0000

 

0.4200

   V0

4/160 (2.5%)

 

4/42 (9.5%)

 

21/77 (27.3%)

 

   V1-3

0/1

 

0/1

 

16/46 (34.8%)

 
  1. ** p < 0.01.
  2. † According to the seventh edition of the International Union Against Cancer TNM guidelines [3].